Côd QR

Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma

BackgroundPosterior reversible encephalopathy syndrome (PRES) is characterized by headaches, vision loss, confusion, encephalopathy, seizures, and reversible focal edema on neuroimaging. Early recognition and treatment of PRES are essential to prevent severe complications. Lenvatinib is a multi-targ...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Minchun Chen, Jing Shen, Rongrong Jia, Mingze Chang, Jingyi Zhang, Jie Zheng, Runqing Xue, Lulu Guo, Kangkang Yan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2025-03-01
Cyfres:Frontiers in Pharmacology
Pynciau:
hepatocellular carcinoma
posterior reversible encephalopathy syndrome
lenvatinib
adverse drug reactions
PRES
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fphar.2025.1487009/full
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg